Relation Between WIF-1 Promoter Methylation and Clinical Pathology of Transitional Carcinoma of Bladder

FU Bin,XU Hua,LANG Bin,XU Kai,ZHANG Jun,MA Xin,AI Xin,ZHOU Huixia,ZHANG Guoxi,WANG Chao,JU Zhenghua,WANG Baojun,SHI Taoping,Zhang Xu

DOI: https://doi.org/10.3969/j.issn.1001-1420.2007.08.027

2007-01-01

Journal of Clinical Urology

Abstract:Objective:To study the Wnt inhibitory factor(WIF-1)promoter methylation and its effect on the protein expression and its relation with clinical pathology of transitional carcinoma of bladder(TCCB).Methods:Methylation-specific PCR was used to detect the methylation status of WIF-1 promoter,and immunohistochemistry was applied to measure WIF-1 protein expression of bladder cancer tissues of 57 patients.Epithelial tissues of normal bladder and glandular cystitis were also tested as control.Results:The methylation rate of bladder cancer,glandular cystitis and normal bladder tissue were 57.9%,15% and 0,respectively(P0.01).The methylation rate significantly increased with tumor grade and stage.The rates of 20%,56.3% and 86.7% were found in grade G1,G2 and G3(P0.01),and 43.8% and 76% in superficial and invasive bladder cancers,respectively(P0.05).The protein expression of WIF-1 was significantly lower in methylated WIF-1 promoter than in unmethylated WIF-1 promoter(P0.001,Kappa value 0.783).Conclusions:The inhibition of WIF-1 protein expression in bladder cancer was related to the WIF-1 promoter methylation.WIF-1 promoter methylation may have an important role on the early stage of carcinogenesis of TCCB,and may also involve in tumor progression.The methylation rate of WIF-1 can be used as a molecular marker to predict the prognosis of patients with TCCB.